[Development for a novel cancer vaccine].
Clinical trial using epitope peptides have been intensively performed in the world. From the results, it has been clarified that tumor specific CTLs were induced in the vaccinated cancer patients. In this manuscript, we demonstrated the problems to be clarified from clinical trial and recent advances for cancer vaccine using epitope peptides.
Tsunoda
Takuya
T
Department of Surgery and Bioengineering Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.
D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D000939:Epitopes / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D020411:Oligonucleotide Array Sequence Analysis; D010455:Peptides / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014614:Vaccines, Synthetic; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000276:immunology
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000939:Epitopes; D010455:Peptides; D014614:Vaccines, Synthetic; D040301:Vascular Endothelial Growth Factor Receptor-2